Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC

BACKGROUND: Patients with human papillomavirus (HPV+) head and neck squamous cell carcinoma (HNSCC) have superior prognoses compared with patients with HPV− HNSCC and strategies for treatment de-escalation are under investigation for the HPV+ setting. However, the survival advantage associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Shanying, O'Neill, W Quinn, Teknos, Theodoros N, Pan, Quintin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978288/
https://www.ncbi.nlm.nih.gov/pubmed/33737336
http://dx.doi.org/10.1136/jitc-2020-001259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978288/
https://www.ncbi.nlm.nih.gov/pubmed/33737336
http://dx.doi.org/10.1136/jitc-2020-001259

Ejemplares similares